Department of Endocrinology, Diabetes and Metabolism, Clinical Chemistry - Division of Laboratory Research, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Endocrine Practice, Molecular Laboratory, Heidelberg, Germany.
Horm Metab Res. 2019 Sep;51(9):568-574. doi: 10.1055/a-0897-8785. Epub 2019 Sep 10.
The aim of this study was to investigate in a longitudinal approach whether levothyroxine (LT4) substitution has a different impact on quality of life (QoL) and thyroid related QoL in younger (<40 years) and older subjects (>60 years) with elevated thyroid-stimulating hormone (TSH) concentrations. The study included male and female patients with newly diagnosed, untreated subclinical hypothyroidism defined by TSH>8 mU/l. Patients were recruited throughout Germany from 2013-2016 and evaluated by clinical assessment, blood sampling and questionnaires for health related QoL and thyroid-disease thyroid-related QoL (ThyPRO) at time of diagnosis and six months after initiation of LT4 treatment. We found significantly lower QoL in both young and old patients with subclinical hypothyroidism compared to age-matched healthy individuals. Higher scores on follow-up were found in all patients irrespective of age, indicating better QoL on LT4 therapy. Analysis of the ThyPRO questionnaire showed that old patients experienced less Emotional Susceptibility, Tiredness, and Impaired Day Life on LT4, while young patients reported less Cognitive Complaints, Emotional Susceptibility, and Impaired Day Life compared to baseline assessment. Hypothyroidism with TSH concentrations>8 mU/l is associated with impairment in general and ThyPRO QoL in young and old age. Older patients benefited from LT4 therapy and remarkably show similar degree of improvement as younger patients, albeit with some thematic variation in ThyPRO QoL. Our data confirm current recommendations on initiation of LT4 substitution and suggest that this should not be withheld in elderly with TSH concentration above 8-10 mU/l.
本研究旨在通过纵向研究探讨左甲状腺素(LT4)替代治疗是否对年轻(<40 岁)和老年(>60 岁)促甲状腺激素(TSH)浓度升高的患者的生活质量(QoL)和甲状腺相关 QoL 产生不同的影响。该研究纳入了新诊断为未经治疗的亚临床甲状腺功能减退症的男性和女性患者,其 TSH>8 mU/l。患者于 2013-2016 年在德国各地招募,并通过临床评估、血液采样和健康相关 QoL 及甲状腺疾病相关 QoL(ThyPRO)问卷进行评估,在诊断时和 LT4 治疗开始后 6 个月进行评估。我们发现,与年龄匹配的健康个体相比,年轻和老年亚临床甲状腺功能减退症患者的 QoL 明显较低。所有患者无论年龄大小,随访时的评分均较高,表明 LT4 治疗可改善 QoL。ThyPRO 问卷分析显示,老年患者在 LT4 治疗后情绪易感性、疲劳和日常活动受限程度较低,而年轻患者与基线评估相比,认知问题、情绪易感性和日常活动受限程度较低。TSH 浓度>8 mU/l 的甲状腺功能减退症与年轻和老年患者的一般和 ThyPRO QoL 受损有关。老年患者受益于 LT4 治疗,与年轻患者相似,尽管在 ThyPRO QoL 方面存在一些主题差异。我们的数据证实了目前关于开始 LT4 替代治疗的建议,并表明不应在 TSH 浓度高于 8-10 mU/l 的老年患者中推迟这种治疗。